Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
WINT 
Windtree Therapeutics Inc (WINT)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/15/2025: WINT (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $4
1 Year Target Price $4
| 0 | Strong Buy |
| 0 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -90.19% | Avg. Invested days 12 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/15/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 3.58M USD | Price to earnings Ratio - | 1Y Target Price 4 |
Price to earnings Ratio - | 1Y Target Price 4 | ||
Volume (30-day avg) 1 | Beta 0.51 | 52 Weeks Range 0.06 - 60.00 | Updated Date 10/17/2025 |
52 Weeks Range 0.06 - 60.00 | Updated Date 10/17/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 62.6 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -34.56% | Return on Equity (TTM) -412.9% |
Valuation
Trailing PE - | Forward PE 0.37 | Enterprise Value 10593533 | Price to Sales(TTM) 660.53 |
Enterprise Value 10593533 | Price to Sales(TTM) 660.53 | ||
Enterprise Value to Revenue 706.08 | Enterprise Value to EBITDA 0.01 | Shares Outstanding 29334220 | Shares Floating 29334220 |
Shares Outstanding 29334220 | Shares Floating 29334220 | ||
Percent Insiders - | Percent Institutions 0.08 |
Upturn AI SWOT
Windtree Therapeutics Inc
Company Overview
History and Background
Windtree Therapeutics, Inc. was founded in 1992. Initially focused on developing surfactant therapies for respiratory distress syndrome (RDS), the company has evolved to address other unmet needs in pulmonary and critical care medicine. They have faced challenges, including regulatory hurdles and financing issues, which have shaped their trajectory.
Core Business Areas
- AEROSURFu00ae: AEROSURFu00ae is an aerosolized form of KL4 surfactant combined with a novel aerosol delivery system designed to provide non-invasive surfactant therapy for premature infants with RDS.
- ISTRADIALu00ae: ISTRADIALu00ae is a pre-clinical product for acute cardiogenic pulmonary edema (ACPE), with potential to improve right ventricular function and treat related conditions.
Leadership and Structure
Craig Fraser serves as the President and CEO. The company's organizational structure consists of executive leadership managing research and development, clinical operations, and finance.
Top Products and Market Share
Key Offerings
- AEROSURFu00ae: AEROSURFu00ae aimed at RDS in premature infants. While initially having potential, AEROSURF faced regulatory setbacks and is no longer in active development by Windtree. Competitors include INSURE (intubation, surfactant administration, and extubation) methods and other surfactant replacement therapies like Survanta (beractant) and Curosurf (poractant alfa). Market share information is unavailable since Windtree does not currently sell this product.
- ISTRADIALu00ae: ISTRADIALu00ae is in pre-clinical development for acute cardiogenic pulmonary edema (ACPE). There is no market share data available as it is not yet approved. Competitors would potentially include diuretics, vasodilators, and inotropes used in the treatment of ACPE.
Market Dynamics
Industry Overview
The pharmaceutical industry is highly competitive and regulated. The sector is subject to extensive research, development, and clinical trial processes. Success depends on innovation, regulatory approval, and effective marketing.
Positioning
Windtree Therapeutics is positioned as a specialty pharmaceutical company focused on addressing unmet needs in respiratory and cardiovascular diseases. Their competitive advantage would rely on the successful development and commercialization of novel therapies.
Total Addressable Market (TAM)
The TAM for ACPE treatments is substantial and is expected to grow with the aging population and increasing prevalence of heart failure. The RDS market, while established, could be significantly impacted by a non-invasive surfactant delivery system. Windtree's position depends on the successful clinical trials and commercialization of ISTRADIAL and potentially a future version of AEROSURF.
Upturn SWOT Analysis
Strengths
- Novel drug delivery technology (potential)
- Focus on unmet medical needs
- Experienced management team
Weaknesses
- Limited financial resources
- Dependence on clinical trial success
- Past regulatory setbacks
- High cash burn rate
Opportunities
- Positive clinical trial results for ISTRADIAL
- Partnerships and collaborations
- Expansion into new therapeutic areas
- Acquisition by a larger pharmaceutical company
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from larger pharmaceutical companies
- Patent expirations
- Inability to raise sufficient capital
Competitors and Market Share
Key Competitors
- Bayer AG (BAYRY)
- Novartis (NVS)
- Abbott (ABT)
Competitive Landscape
Windtree faces significant competition from larger, more established pharmaceutical companies. Its success depends on demonstrating superior efficacy and safety in clinical trials and securing regulatory approvals.
Growth Trajectory and Initiatives
Historical Growth: Windtree's historical growth has been limited, primarily driven by advancements in its product pipeline.
Future Projections: Future growth is heavily reliant on the successful development and commercialization of ISTRADIAL. Analyst estimates are highly speculative due to the inherent risks of drug development.
Recent Initiatives: Recent initiatives include focusing on the development of ISTRADIAL and seeking partnerships to support clinical development and commercialization.
Summary
Windtree Therapeutics is a high-risk, high-reward biotechnology company focused on developing therapies for respiratory and cardiovascular diseases. The company faces financial challenges and regulatory hurdles, but successful clinical trials and commercialization of its products could lead to significant returns. Investors should closely monitor clinical trial results and financial performance. The company's ability to secure funding and partnerships is critical for its long-term success.
Peer Comparison
Sources and Disclaimers
Data Sources:
- SEC Filings
- Company Website
- Analyst Reports (where available)
- Market Research Reports
Disclaimers:
This analysis is based on publicly available information and is not financial advice. Investing in biotechnology companies is inherently risky, and investors should conduct their own due diligence before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Windtree Therapeutics Inc
Exchange NASDAQ | Headquaters Warrington, PA, United States | ||
IPO Launch date 1995-08-08 | CEO, President & Director Mr. Jed A. Latkin | ||
Sector Healthcare | Industry Biotechnology | Full time employees 14 | Website https://windtreetx.com |
Full time employees 14 | Website https://windtreetx.com | ||
Windtree Therapeutics, Inc., a biotechnology company, focuses on the development of therapeutics for the treatment of acute cardiovascular diseases. Its lead product candidate is istaroxime, which is in Phase 2b clinical trials for the treatment of acute decompensated heart failure, as well as for the treatment of early cardiogenic shock. The company also develops AEROSURF, an aerosolized KL4 surfactant that is in Phase 2b clinical trials to treat respiratory distress syndrome in premature infants; Surfaxin, a lyophilized KL4 surfactant for the treatment of respiratory disease, disorder, or condition in humans; Rostafuroxin, which is in Phase 2b clinical trials for the treatment of genetically associated hypertension; and oral and intravenous SERCA2a activators, which are in preclinical trials for the treatment of chronic and acute heart failure. In addition, it is developing an aPKCi inhibitor, which is in preclinical trials for the treatment of cutaneous malignancies and solid tumors. Windtree Therapeutics, Inc. has a strategic alliance with Laboratorios del Dr. Esteve, S.A. for the development, marketing, and sale of a portfolio of potential KL4 surfactant products; a license, development, and commercialization agreement with Lee's Pharmaceutical (HK) Ltd. and Zhaoke Pharmaceutical (Hefei) Co. Ltd.; a license agreement with Philip Morris USA, Inc. and Johnson & Johnson; and a collaboration with Battelle Memorial Institute for the development of its aerosol delivery system. The company was formerly known as Discovery Laboratories, Inc. and changed its name to Windtree Therapeutics, Inc. in April 2016. Windtree Therapeutics, Inc. was founded in 1992 and is headquartered in Warrington, Pennsylvania.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.